文献速递细菌感染、耐药与抗菌药物医院感染防控

近距离放疗中抗菌药物预防的作用:前列腺、乳腺及妇科癌症叙述性综述

The role of antimicrobial prophylaxis in brachytherapy for prostate, breast and gynaecological cancer: a narrative review.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

本叙述性综述总结了前列腺、乳腺及妇科(宫颈和子宫内膜)癌症近距离放疗的感染并发症及抗菌药物预防的潜在获益。感染并发症发生率仍较低但预防方案多样,抗菌药物方案、器械类型和操作方式影响感染概率,现有近距离放疗指南与手术预防指南重叠极少,感染结局和耐药性报道不足,耐药菌指导匮乏;有指征时预防用药少于24小时有效,需针对该人群开展更多研究。

要点

  • 前列腺、乳腺及妇科癌症近距离放疗感染并发症率仍较低,但预防方案多样,需识别危险因素以制定个体化实践。
  • 抗菌药物方案选择、器械类型和操作方式影响感染并发症概率。
  • 有指征时,预防用药少于24小时有效;现有近距离放疗指南与手术预防指南重叠极少。

核心结论

  • 近距离放疗感染并发症率低但预防方案多样,抗菌药物方案、器械类型和操作方式影响感染概率,需识别危险因素以制定个体化实践。

研究设计与样本

  • 叙述性综述,总结前列腺、乳腺及妇科(宫颈和子宫内膜)癌症近距离放疗的感染并发症及抗菌药物预防的潜在获益。

主要发现

  • 前列腺、乳腺及妇科癌症近距离放疗的感染并发症发生率仍较低,预防方案多样。
  • 抗菌药物方案选择、器械类型和操作方式影响感染并发症概率。
  • 现有近距离放疗指南与手术预防指南重叠极少。
  • 感染结局和抗菌药物耐药性报道不足,耐药菌指导匮乏。
  • 有指征时,预防用药少于24小时有效。

关键数值与推荐

  • 有指征时,预防用药少于24小时有效。

临床怎么用

  • 有指征时,预防用药少于24小时有效。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Proper antimicrobial prophylaxis is critical for reducing the risk of infection during interventional procedures. Brachytherapy, a highly effective radiation therapy for various malignancies, allows for precise radiation delivery; however, the use of foreign material as instrumentation for brachytherapy potentially increases the risk of infection. Understanding infectious complications and proper antimicrobial use in this case is essential for successful outcomes and patient safety. The aim of this review is to provide insights and summarize existing information on the infectious complications of brachytherapy in prostate, breast and gynaecological (cervical and endometrial) cancer, as well as on the potential benefit, if any, of administering antimicrobial prophylaxis. Infectious complication rates in prostate, breast and gynaecological cancer brachytherapy remain low with diverse prophylactic regimens, emphasizing the need to identify risk factors for tailored practices. The choice of the antimicrobial regimen, type of device and modality influences the probability of infectious complications. There is minimal overlap of existing brachytherapy guidelines with surgical prophylaxis guidelines. Infectious outcomes and antimicrobial resistance are underreported, and guidance for antimicrobial-resistant organisms is scarce. When indicated, prophylaxis for less than 24 h is efficient. More studies oriented towards antimicrobial prophylaxis on this specific population are needed.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Alexakis K, Strouthos I, Agouridis AP, et al. The role of antimicrobial prophylaxis in brachytherapy for prostate, breast and gynaecological cancer: a narrative review. J Antimicrob Chemother. 2025. PMID: 40357742. doi:10.1093/jac/dkaf139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。